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ADVANCED CARE PLANNING (ACP) BEFORE STEM CELL TRANSPLANTA-
TION (SCT) TREATMENT BEGINS
Neumann, J.L., Gallagher, C., Epner, D., Susan, G., Buitrago, J.,
Richard, C. The University of Texas MD Anderson Cancer Center, Hous-
ton, TX
SCT is a high risk/reward proposition. Many experienced SCT
practitioners perceive that SCT patients are not consistently pre-
pared for the possibility of life threatening complications and
poor outcomes. The SCT department was selected to pilot
a patient-centered intervention to improve ACP discussions in
our institution. ACP is an extraordinarily complex process, and
many patient, provider, and system factors influence whether dis-
cussions occur.
Aim: Increase SCT patients’ awareness of the possibility of life
threatening complications and poor outcomes by examining the
number of advance directives (AD) and/or documentation of ACP
conversations by at least 10%.
Interventions: A patient-centered educational initiative was devel-
oped. An existing admission class was enhanced by distributing a pre-
viously created ACP document. Salient points were discussed and
patients were encouraged to talk to their providers prior to admission
if they had any additional questions or concerns.
Results: A chart audit for documentation of ACP discussions and
AD documents before (N 5 32) and after (N 5 35) the intervention
was used. A patient survey was used to assess the patients’ response to
ACP information presented in the class. Twelve (37%) AD docu-
ments were found before the intervention and 14 (40%) after. Doc-
umentation of the conversations between patients and providers
(MD, PA, SW) occurred with 23 (72%) patients before the interven-
tion and 31 (89%) after the intervention. Patient evaluations indi-
cated the majority agreed or strongly agreed that this information
was understandable, useful and prompted them to think about deci-
sions and discussions theymay need to have with family and care pro-
viders.
Conclusions: Because of the brief duration, we were unable to
identify cost savings. However, based on improved understanding
of ACP and patient-provider shared determinations of best pa-
tient-centered practice, further investigation is warranted which
will include review of length of stay and changes in ICU usage
and related cost savings. We have continued the intervention and
are collecting additional data. Interventions will be modified as in-
dicated, and we will continue to work on developing other metrics.
Further, we plan to examine more specifically the meaning of a sub-
stantive conversation, leading to the development of trigger points
for discussions. We ultimately expect to develop guidelines and
training for providers, and continue to promote the importance
of ACP.574
INTEGRATING HSCT EVALUATION-PHASE ACTIVITIES TO REDUCE COST
AND STREAMLINE WORKFLOW
Kostaras, P.M., Emmert, A.E. Dana-Farber/Brigham &Women’s Can-
cer Center, Boston, MA
The evaluation process required for insurance approval for
HSCT occurs alongside the clinical work-up process which is
in part governed by eligibility assessment standards set by
FACT, the FDA, and other regulatory bodies. In a large academic
cancer center, the functional differentiation among clinical staff,
financial registrars and counselors, and transplant coordinators
supporting patient case management during the evaluation phase
for HSCT tends to generate separate standard work flows for
each function, leading to inefficiency among staff and overuse
of clinical testing. A workflow and decision tree analysis demon-
strated an opportunity to create a single process engaging all co-
ordination and clinical evaluation functions to reduce time to
insurance approval, reduce overall effort for staff, reduce excess
testing, and produce greater clarity and comfort for patients.
Benefit review and documentation, testing requirements, hand-
offs for appropriate peer to peer discussion and negotiation
were all addressed as distinct processes that required optimizedand integrated process improvement. The new workflow involves
time point requirements and decision trees to ensure consistency
and compliance. A focus on reducing non-critical or repeat test-
ing generated a greater use of existing testing results and the ed-
ucation of payer case managers in FACT and cancer center
eligibility standards effectively reduced requirements for early
or up front testing that would need to be repeated prior to admis-
sion. Implementation revealed further opportunities for stream-
lining which were incorporated into the process. Outcomes
show marked reduction/elimination of non-clinically valuable or
duplicate testing, faster insurance authorization, and greater
throughput relative to staffing levels.575
EFFORTS TO MANAGE AND REDUCE DISCHARGE PHARMACY CRISES
AMONG HIGH RISK HSCT PATIENTS
Gaumer, C., Holland, D., Emmert, A. Dana-Farber/Brigham & Wom-
en’s Cancer Center, Boston, MA
The HSCT program at Dana-Farber/Brigham and Women’s
Cancer Center was experiencing increasing instances of unex-
pected pharmacy benefit crises and associated delayed dis-
charge, provision of emergency medications at time of
discharge at the expense of the hospital, and last minute crisis
management by many staff members. After review and analysis
of the root causes for these problems, an infrastructure was es-
tablished to focus on early intervention during the HSCT work-
up process to identify and address a set of risks associated with
a significant subset of HSCT patients, including psychosocial
support needs, lack of outpatient caregiver, financial shortfalls,
complex pharmacy benefit plans and insurance restrictions
that contribute to medication access crises. New positions
were proposed and filled – an Ambulatory Care Coordination
Nurse (ACCRN) and a Pharmacy Resource Specialist (PRS).
These key resources work together with other members of pa-
tients’ transplant team from social work, ambulatory and inpa-
tient care coordination, the clinical team, the transplant
coordination team, and financial counseling staff. The ACCRN
researches the patient’s high risk issues, incorporating patient
information provided by other team members to plan a safe
and organized discharge. Pharmacy benefits and calculation of
the expected pharmacy costs are presented to the patient in
advance of the transplant admission. The PRS researches drug
assistance programs as needed. The CCRN and the PRS discuss
drug coverage options with the patient and assist with comple-
tion of necessary paperwork. After 18 months of service, this
effort has yielded significantly fewer discharge medication is-
sues, has reduced emergency medication dispensing at the
time of discharge, generated a smoother discharge path for
the inpatient care coordination and clinical team, generated
greater patient satisfaction and understanding of post transplant
care and costs, and reduced instances of extended days in hos-
pital due to delayed discharge.576
ASSESSMENT AND REVISION OF PATIENT SCHEDULING FOR HSCT
RELATED APHERESIS AND CELL PROCESSING TO REDUCE OVER-
ALLOCATION AND UNDERUTILIZATION OF RESOURCES
King, B.S., Ellis, M., Schott, D.M., Kostaras, P.M., Emmert, A.E.
Dana-Farber/Brigham & Women’s Cancer Center, Boston, MA
With the initiation of the use of plerixafor and its impact on
apheresis flow and utilization relative to HSCT in a large aca-
demic cancer center, resulting disruptive shifts in utilization
prompted an evaluation of the scheduling processes supporting
the clinical and product pathway from apheresis through pro-
cessing and issuing of products for infusion. Several opportuni-
ties for improvement in staffing, resource scheduling process,
communication, and distribution of work process across time
periods were identified. An analysis of historical volume of
